Gilead Sciences (GILD) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.
The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.
The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.
The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.
Gilead shares were down 2% in recent trading.
Price: 114.77, Change: -2.44, Percent Change: -2.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.